Aclarion, Inc. has published a shareholder letter from CEO Brent Ness outlining the company's strategic progress and priorities for 2026, focusing on expanding adoption of its Nociscan platform for chronic low back pain diagnosis. The update highlights momentum in clinical evidence development, reimbursement initiatives, and commercial engagement as the company approaches several important milestones.
The company is pursuing reimbursement coverage from regional insurance providers in the United States as a critical step toward broader payer adoption. This initiative represents a significant development in healthcare economics, as insurance coverage often determines whether innovative medical technologies become accessible to patients. Successful reimbursement could accelerate adoption of Nociscan, which uses biomarkers and augmented intelligence algorithms to help physicians identify painful discs in the lumbar spine.
Aclarion's ongoing CLARITY clinical trial represents another major catalyst, with an initial readout expected in the fourth quarter of 2026. Clinical evidence from this trial could strengthen the platform's scientific foundation and support broader clinical adoption. The company's strong balance sheet with cash runway into 2028 provides financial stability to execute these initiatives without immediate funding concerns.
The Nociscan platform represents a novel approach to a widespread healthcare challenge. Chronic low back pain affects millions globally and often leads to extensive diagnostic procedures and treatments without clear identification of pain sources. By noninvasively distinguishing between painful and nonpainful discs using magnetic resonance spectroscopy data processed through proprietary algorithms, Nociscan aims to provide physicians with clearer diagnostic information to optimize treatment strategies.
For more information about the company's technology, visit https://www.aclarion.com. The full CEO shareholder letter is available on the company's website, and additional company news can be found at https://tinyurl.com/aconnewsroom.
The strategic update matters because chronic low back pain represents a substantial burden on healthcare systems and patients worldwide, with current diagnostic approaches often failing to precisely identify pain sources. Aclarion's progress toward insurance reimbursement and clinical validation could potentially transform diagnostic approaches for this condition, leading to more targeted treatments and reduced healthcare costs. The company's focus on building both clinical evidence and payer support addresses two critical barriers to medical technology adoption, making their 2026 milestones potentially significant for patients, physicians, and healthcare systems seeking more effective approaches to chronic pain management.
